These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24325938)

  • 41. Formulation and evaluation of novel reverse microemulsions containing salmon calcitonin in hydrofluoroalkane propellants.
    Shan Z; Tan Y; Qin L; Li G; Pan X; Wang Z; Yu X; Wang Q; Wu C
    Int J Pharm; 2014 May; 466(1-2):390-9. PubMed ID: 24657140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthma.
    Nicolini G; Chetta A; Simonazzi A; Tzani P; Aiello M; Olivieri D
    Allergy Asthma Proc; 2010; 31(5):85-90. PubMed ID: 20929599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of two methods to determine the solubility of compounds in aerosol propellants.
    Gupta A; Myrdal PB
    Int J Pharm; 2005 Mar; 292(1-2):201-9. PubMed ID: 15725567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
    Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P
    Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro performance of two common valved holding chambers with a chlorofluorocarbon-free beclomethasone metered-dose inhaler.
    Asmus MJ; Coowanitwong I; Kwon SH; Khorsand N; Hochhaus G
    Pharmacotherapy; 2003 Dec; 23(12):1538-44. PubMed ID: 14695033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is inhaled beclomethasone (BDP) with a non-CFC propellant equivalent to the CFC propellant formulations?
    Chrystyn H
    Respir Med; 2000 Feb; 94(2):177-9; author reply 179-80. PubMed ID: 10714428
    [No Abstract]   [Full Text] [Related]  

  • 48. Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics.
    Selvam P; Bharatwaj B; Porcar L; da Rocha SR
    Int J Pharm; 2012 Jan; 422(1-2):428-35. PubMed ID: 22044539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers.
    Sharma K; Somavarapu S; Colombani A; Govind N; Taylor KM
    Eur J Pharm Biopharm; 2012 May; 81(1):74-81. PubMed ID: 22245573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate.
    Dahl R; Ringdal N; Ward SM; Stampone P; Donnell D
    Br J Clin Pract; 1997; 51(1):11-5. PubMed ID: 9158265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro characterization of the OptiChamber Diamond valved holding chamber.
    Hatley RH; von Hollen D; Sandell D; Slator L
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27 Suppl 1():S24-36. PubMed ID: 25054480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma.
    Teramoto T; Fukao T; Tomita Y; Terauchi Y; Hosoi K; Matsui E; Aoki M; Kondo N; Mikawa H
    Allergol Int; 2006 Sep; 55(3):317-20. PubMed ID: 17075274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers.
    Gupta A; Stein SW; Myrdal PB
    J Aerosol Med; 2003; 16(2):167-74. PubMed ID: 12823910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HFA inhalers.
    Koninck JC; Magro P; Khanjari F; Lemarié E; Diot P
    Pediatr Pulmonol Suppl; 2004; 26():23-5. PubMed ID: 15029583
    [No Abstract]   [Full Text] [Related]  

  • 55. Surface energy and interparticle forces correlations in model pMDI formulations.
    Traini D; Rogueda P; Young P; Price R
    Pharm Res; 2005 May; 22(5):816-25. PubMed ID: 15906178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of the storage orientation on the aerodynamic particle size of a suspension metered dose inhaler containing propellant HFA-227.
    Berry J; Kline LC; Hart JL; Sequeira J
    Drug Dev Ind Pharm; 2003 Jul; 29(6):631-9. PubMed ID: 12889781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multimodal particle size distributions emitted from HFA-134a solution pressurized metered-dose inhalers.
    Smyth HD; Hickey AJ
    AAPS PharmSciTech; 2003; 4(3):E38. PubMed ID: 14621970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers.
    Nyambura BK; Kellaway IW; Taylor KM
    Int J Pharm; 2009 Jun; 375(1-2):114-22. PubMed ID: 19481697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pharmacokinetics of inhaled hydrofluoroalkane formulations.
    Borgström L
    J Allergy Clin Immunol; 1999 Dec; 104(6):S246-9. PubMed ID: 10588984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing the primary particle size distributions of pressurized metered dose inhalers by using inkjet spray drying for targeting desired regions of the lungs.
    Ehtezazi T; Davies MJ; Seton L; Morgan MN; Ross S; Martin GD; Hutchings IM
    Drug Dev Ind Pharm; 2015 Feb; 41(2):279-91. PubMed ID: 24252108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.